| n = 115 |
---|---|
Characteristic | n (%) |
Male sex | 77 (67.0) |
Median age, years (range) | 59 (23–82) |
AJCC stage | Â |
 Unresectable stage III | 16 (13.9) |
 M1a/M1b | 41 (35.7) |
 M1c | 58 (50.4) |
Serum LDH at baseline | Â |
 Normal | 65 (56.5) |
 Above normal | 47 (40.9) |
ECOG performance status | Â |
 0 | 67 (58.3) |
 1 | 48 (41.7) |
Prior systemic therapy | Â |
 None | 52 (45.2) |
 Interferon, IL-2, GM-CSF | 59 (51.3) |
 Investigational therapy | 4 (3.5) |
Treatment arm | Â |
 Carboplatin/paclitaxel | 58 (50.4) |
 Carboplatin/paclitaxel/sorafenib | 57 (49.6) |
BRAF status | Â |
 Mutant | 48 (41.8) |
 V600E | 34 (29.6) |
 V600K | 8 (7.0) |
 V600R | 3 (2.6) |
 V600D | 1 (0.9) |
 K601E | 2 (1.7) |
 Wild-type | 52 (45.2) |
 Unknown | 15 (13.0) |
NRAS status | Â |
 Mutant | 22 (19.1) |
 G13R | 2 (1.7) |
 G13C | 1 (0.9) |
 Q61R | 9 (7.8) |
 Q61K | 8 (7.0) |
 D61L | 2 (1.7) |
 Wild-type | 78 (67.8) |
 Unknown | 15 (13.0) |
Survival | Â |
 Median OS, months (range) | 9.8 (0.5–56.9) |
 Median PFS, months (range) | 4.4 (0.5–42.1) |